Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays

19 Oct 2020

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to HER2/EGFR in Cancer Research
Share to Molecular Biology Techniques and Applications

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33077919
DOI: 10.1038/s41379-020-00695-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assaysPMID 33077919Read ↗

Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.Semantic proximity Read ↗

Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.Semantic proximity Read ↗

Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.Semantic proximity Read ↗

HER2 Evaluation in Uterine Serous Carcinoma: Diagnostic Agreement Between Biopsy and Resection SamplesSemantic proximity Read ↗

Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.Semantic proximity Read ↗

The Rapidly Evolving Landscape of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Endometrial Carcinoma and Other Gynecologic Malignancies.Semantic proximity Read ↗

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.Semantic proximity Read ↗

Evaluation of somatic mutations in cervicovaginal samples as a non-invasive method for the detection and molecular classification of endometrial cancer.Semantic proximity Read ↗

Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification StatusSemantic proximity Read ↗

HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.Semantic proximity Read ↗

ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.Semantic proximity Read ↗

Updates in therapy for uterine serous carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.